Teligent is a specialty generic pharmaceutical company which develops, formulates, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products. The Company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The Company's products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract formulation and contract manufacturing services.

Type
Public
HQ
Buena, US
Founded
1977
Size (employees)
153 (est)+43%
Teligent was founded in 1977 and is headquartered in Buena, US
Report incorrect company information

Key People/Management at Teligent

Jason Grenfell-Gardner

Jason Grenfell-Gardner

President & CEO
Damian Finio

Damian Finio

Chief Financial Officer
Steve Richardson

Steve Richardson

Chief Scientific Officer
Martin Wilson

Martin Wilson

General Counsel
Barbara Lani

Barbara Lani

Senior Vice President, Quality
Mark Mantel

Mark Mantel

General Manager, Canada
Show more

Teligent Office Locations

Teligent has offices in Toronto, Buena, Tallinn and Iselin
Buena, US (HQ)
105 Lincoln Avenue
Iselin, US
33 South Wood Ave, Suite 730
Toronto, CA
10 King Street East Suite 1500
Tallinn, EE
21/5 Akadeemia tee
Show all (4)
Report incorrect company information

Teligent Financials and Metrics

Teligent Financials

Teligent's revenue was reported to be $67.25 m in FY, 2017
USD

Revenue (FY, 2017)

67.3 m

Gross profit (FY, 2017)

27.4 m

Gross profit margin (FY, 2017), %

40.7%

EBIT (FY, 2017)

(11.8 m)

Market capitalization (31-Oct-2017)

303.3 m

Closing share price (31-Oct-2017)

5.8

Cash (31-Dec-2017)

26.7 m
Teligent's current market capitalization is $303.3 m.
Annual
USDFY, 2016FY, 2017

Revenue

66.9 m67.3 m

Cost of goods sold

32.2 m39.9 m

Gross profit

34.7 m27.4 m

Gross profit Margin, %

52%41%
Quarterly
USDQ1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Revenue

6.9 m6.7 m10.7 m8.9 m11.6 m15.7 m17.1 m16.2 m19.9 m51.2 m

Cost of goods sold

4 m4 m5 m5.2 m5.5 m7.7 m7.6 m8.1 m9 m29.6 m

Gross profit

2.9 m2.6 m5.6 m3.7 m6.1 m8 m9.6 m8 m10.9 m21.5 m

Gross profit Margin, %

42%39%53%41%52%51%56%50%55%42%
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

87.2 m66 m26.7 m

Accounts Receivable

14 m21.7 m18.1 m

Inventories

9 m12.7 m16.1 m

Current Assets

116.8 m103.3 m64.5 m
Quarterly
USDQ1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Cash

2.4 m23.2 m157 m150.2 m145.7 m87 m81.2 m74.6 m59.5 m38.2 m

Accounts Receivable

4.1 m6.4 m16.3 m17.3 m10.9 m13.2 m15.5 m17.2 m25.2 m25 m

Inventories

2.7 m3.2 m3.7 m4.1 m5 m10.1 m11 m12.5 m14.3 m14.2 m

Current Assets

9.9 m33.8 m178.4 m173.1 m163 m117.7 m110.6 m106.9 m101.9 m79.8 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

6.7 m(12 m)(15.2 m)

Inventories

(3.6 m)(5 m)(5.3 m)

Accounts Payable

(2.8 m)4.7 m5.7 m

Cash From Operating Activities

(15.5 m)1.1 m400 k
Quarterly
USDQ1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

167 k(202 k)6.6 m9.4 m(2.9 m)(950 k)(2.9 m)(2.7 m)831 k(9.1 m)

Inventories

4.1 m5 m10.1 m11 m12.5 m14.3 m(2.8 m)

Accounts Payable

2.6 m3 m4.4 m4 m3.8 m8.1 m4 m

Cash From Operating Activities

(2.7 m)
USDY, 2017

Revenue/Employee

517.3 k

Financial Leverage

4.2 x
Show all financial metrics
Report incorrect company information

Teligent News and Updates

BRIEF-FDA Grants Teligent Approval Of Ciclopirox Shampoo, 1%

* TELIGENT, INC. ANNOUNCES FDA APPROVAL OF CICLOPIROX SHAMPOO, 1%
Report incorrect company information